secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clearside Biomedical, Inc. (CLSDQ)
CIK:        0001539029
Form:       8-K
Filed at:   2025-09-08T23:59:59+00:00
Accession:  0000950170-25-113362
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Clearside Biomedical receives additional $3M from Healthcare Royalty; reduces royalty cap
--------------------------------------------------------------------------------

- Company entered Omnibus Amendment with Healthcare Royalty Partners; received $3.0M for remaining SCS Microinjector assets.
- Royalty threshold for expiration reduced from $110.5M to $106.5M; potential lower future payments.
- Purchaser waived right to foreclose on Seller capital stock in specified circumstances.
- All other terms of original 2022 Purchase/Sale and Contribution Agreements remain unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1539029/000095017025113362/0000950170-25-113362-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1539029/000095017025113362/clsd-20250904.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-113362

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer